• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Prostatype Genomics

0.16 SEK-0.93 %27.7, 17.29
Less than 1K followers

PROGEN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
-0.93 %
-10.72 %
-46.77 %
-78.38 %
+40.18 %
-60.51 %
-99.36 %
-99.94 %
-99.88 %

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Read more
Market cap
85.23M SEK
Turnover
1.08M SEK
Revenue
594K
EBIT %
-6,555.22 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
31.8
2026

Interim report Q2'26

11.2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release27.07.2026, 18.00

Prostatype Genomics AB announces outcome in rights issue of units

Prostatype Genomics
Regulatory press release21.07.2026, 08.00

Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026

Prostatype Genomics
Regulatory press release09.07.2026, 08.30

The subscription period in Prostatype Genomics AB's rights issue of units begins today

Prostatype Genomics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release08.07.2026, 20.45

Prostatype Genomics AB publishes information memorandum prior to rights issue of units

Prostatype Genomics
Regulatory press release08.07.2026, 19.45

Prostatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of units

Prostatype Genomics
Regulatory press release29.06.2026, 20.00

The Board of Directors of Prostatype Genomics AB resolves on the previously announced rights issue of units of approximately SEK 47.4 million

Prostatype Genomics
Regulatory press release22.06.2026, 18.45

Bulletin from annual general meeting in Prostatype Genomics AB (publ)

Prostatype Genomics
Regulatory press release01.06.2026, 10.45

Prostatype Genomics publishes Annual Report for 2025

Prostatype Genomics
Regulatory press release25.05.2026, 08.45

Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype® in the United States

Prostatype Genomics
Regulatory press release19.05.2026, 22.00

NOTICE OF ANNUAL GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)

Prostatype Genomics
Regulatory press release19.05.2026, 21.50

Prostatype Genomics AB announces the Board of Directors’ intention to resolve on a rights issue of units of approximately SEK 47.4 million

Prostatype Genomics
Regulatory press release26.02.2026, 16.45

Prostatype Genomics publishes year-end report for 2025

Prostatype Genomics
Regulatory press release12.01.2026, 08.55

Loan financing of SEK 10 million to Prostatype Genomics AB

Prostatype Genomics
Regulatory press release08.01.2026, 19.30

Prostatype Genomics U.S. Validation study by Veterans Affairs (VA) is published

Prostatype Genomics
Regulatory press release25.11.2025, 14.30

Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results

Prostatype Genomics
Press release19.11.2025, 08.06

BioStock: Video from Prostatype Genomic's presentation at BioStock Life Science Summit 2025

Prostatype Genomics
Regulatory press release11.11.2025, 15.45

Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics

Prostatype Genomics
Regulatory press release24.09.2025, 22.45

New shares from exercise of warrants of series TO5 registered

Prostatype Genomics
Regulatory press release18.09.2025, 19.00

Prostatype Genomics AB receives SEK 11.5 million in connection with warrants of series TO5

Prostatype Genomics
Regulatory press release12.09.2025, 09.05

The last day of trading in Prostatype Genomics AB’s warrants of series TO5 is on Monday

Prostatype Genomics